The mechanisms underlying tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia (CML) patients lacking explanatory BCR-ABL1 kinase domain mutations are incompletely understood. To identify mechanisms of TKI resistance that are independent of BCR-ABL1 kinase activity, we introduced a lentiviral short hairpin RNA (shRNA) library targeting ∼5000 cell signaling genes into K562 R , a CML cell line with BCR-ABL1 kinaseindependent TKI resistance expressing exclusively native BCR-ABL1. A customized algorithm identified genes whose shRNA-mediated knockdown markedly impaired growth of K562 R cells compared with TKI-sensitive controls. Among the top candidates were 2 components of the nucleocytoplasmic transport complex, RAN and XPO1 (CRM1). shRNA-mediated RAN inhibition or treatment of cells with the XPO1 inhibitor, , increased the imatinib sensitivity of CML cell lines with kinase-independent TKI resistance. Inhibition of either RAN or XPO1 impaired colony formation of CD34 1 cells from newly diagnosed and TKI-resistant CML patients in the presence of imatinib, without effects on CD34 1 cells from normal cord blood or from a patient harboring the BCR-ABL1 T315I mutant. These data implicate RAN in BCR-ABL1 kinase-independent imatinib resistance and show that shRNA library screens are useful to identify alternative pathways critical to drug resistance in
Introduction
Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy caused by BCR-ABL1, a constitutively active tyrosine kinase derived from a reciprocal translocation between chromosomes 9 and 22. In the chronic phase of CML (CML-CP), myeloid cell differentiation and function remain intact. However, without effective therapy, CML-CP progresses to a treatment refractory acute leukemia termed blastic phase. 1 CML-CP is effectively managed with the BCR-ABL1 tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, or dasatinib. Despite impressive results, ;20% of newly diagnosed CML-CP patients fail imatinib because of drug resistance, with lower resistance rates recently reported for dasatinib and nilotinib. [2] [3] [4] BCR-ABL1 kinase domain mutations that impair drug binding are the best-characterized mechanism of resistance. [5] [6] [7] [8] However, many patients develop TKI resistance with native BCR-ABL1 or kinase domain mutations predicted to be TKI sensitive. In these patients, resistance involves activation of survival signals by either intrinsic, cell autonomous mechanisms or extrinsic, bone marrow-derived factors, and targeting these signals may resensitize CML cells to TKIs. The mechanisms responsible for BCR-ABL1 kinase-independent TKI resistance are incompletely understood. Genome-wide scanning techniques such as gene expression arrays and whole genome sequencing have been previously used to search for resistance mechanisms. [9] [10] [11] [12] [13] [14] Although powerful, these assays are not function based and may miss critical genes if they are neither mutated nor characterized by changes in expression. Here, we used a function-first, short hairpin RNA (shRNA)-based forward screen in BCR-ABL1-positive cell lines and primary CML CD34 1 cells to identify nucleocytoplasmic transport as a critical feature of BCR-ABL1 kinase-independent resistance in CML.
Materials and methods

Imatinib-sensitive and imatinib-resistant cell lines
All cell lines were cultured in RPMI medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 100 U/mL penicillin/streptomycin (RF10). Imatinib-sensitive K562 and AR230 (K562 S and AR230 S ) cells were cultured in escalating concentrations of imatinib over several months, resulting in imatinib-resistant derivative lines (K562 R and AR230 R ), as described. 15 Imatinib-resistant K562 R and AR230 R cells are resistant to multiple TKIs, including dasatinib and nilotinib. 16 Steady-state conditions for TKI-sensitive cells are culture without imatinib. Steady-state conditions for TKI-resistant cells are culture with 1.0 mM imatinib. See also supplemental Methods (available on the Blood Web site).
Patient samples
Prior to use in assays, fresh or frozen CD34 1 cells were cultured in Iscove modified Dulbecco medium supplemented with 10% BIT9500 (StemCell Technologies, Vancouver, BC, Canada) supplemented with cytokines (CC100; StemCell Technologies) for 24 to 48 hours at 37°C. All donors gave informed consent, and the University of Utah Institutional Review Board approved all studies. See also supplemental Methods and supplemental Table 1 .
Library module and packaging
Cellecta provided the Human Module 1 (HM1) lentiviral shRNA library containing ;27 500 shRNAs targeting ;5000 genes involved in cell signaling with 5 to 6 shRNAs per gene (http://www.cellecta.com/index.php). The lentiviral expression vector contains a puromycin-resistance gene (Puro R ) and a red fluorescent protein (RFP) marker (TagRFP). Each shRNA is linked to a unique 18-bp barcode identifiable by sequencing. For virus production, see supplemental Methods.
shRNA library screen Steady-state K562 R (cultured in 1 mM imatinib) or K562 S cells were suspended in RF10 and distributed to 6-well plates at 10 6 /well with polybrene (2 mg) and 15 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid buffer (pH: 7.2). K562 R or K562 S cells were then infected with virus at a multiplicity of infection of 1, followed by spinoculation; see supplemental Methods. At 72 hours, cells were analyzed for RFP expression, and half were snap frozen for use as controls. Puromycin (1 mg/mL) was added to the second half to eliminate uninfected cells, followed by a 9-day culture in RF10 6 1 mM imatinib with medium changes and expansions to maintain exponential growth. After 9 days, cells were collected, DNA extracted, and barcodes amplified as recommended by Cellecta (Pooled Barcoded Lentiviral shRNA library v5, http://www.cellecta.com/resources/protocols). Amplification was done with the lowest possible number of cycles (,14 cycles for each step) to minimize biased amplification of barcodes. Amplicons sizes were checked on a 3% agarose gel using GeneRuler Ultra Low Range DNA Ladder (Thermo Scientific, Waltham, MA), then purified (PCR Clean-Up Kit, Qiagen, Valencia, CA). Polymerase chain reaction (PCR) products were sequenced to high depth (Illumina HiSequation 2000). Refer to Kampmann et al for additional information regarding genome-wide screening techniques utilizing shRNA libraries. 17 
Bioinformatics analysis
Fastq files were processed with Decipher's BarCode Deconvoluter x64 program. Output consisted of TAB files for each sample harboring all sequences matching exactly 1 of the 27 495 18-bp barcodes present in the HM1 library file. Internal code was developed to count frequencies of each barcode present in each sample, with subsequent merging of barcode and gene name identified within the library file. There were 5 to 6 barcodes (unique shRNAs) for 5034 genes and 2 barcodes for 1 gene (an additional 9 overrepresented genes were removed from consideration; luciferase controls were also overrepresented) yielding a total of 27 246 useable barcodes. A median read depth of 4711 to 5153 was obtained for matching barcodes across samples. As total reads per lane (and hence sample) vary, each sample's reads were adjusted to equalize the total read counts across samples prior to foldchange calculations. No sample was adjusted by more than 4.2%. Distinct bimodal distributions were observed for read depth in each sample, with 99.98% of reads falling in the lower mode (,;1000 reads) corresponding to nonspecific binding, and 99.64% of reads in the upper mode corresponding to HM1 barcodes (supplemental Figure 1 ). Fold-change between captured reads on day 9 in the sensitive line and the median of reads on day 9 in the corresponding resistant line were calculated with additive adjustments of 20 to both numerator and denominator to mitigate potential low-read bias in foldchange calculations. For correlation between trials run at the Huntsman Cancer Institute vs trials run at Cellecta, both Spearman and Pearson methods were used.
Tetracycline-inducible constructs and messenger RNA (mRNA) expression analysis
For select candidate genes, shRNAs with the highest depletion during the screening were inserted into a tetracycline-inducible vector (pRSIT12-U6Tet-CMV-TetR-2A-TagRFP-2A-Puro, Cellecta) containing the wild-type tetracycline repressor (tetR), which blocks transcription unless 0.1 mg/mL doxycycline is added. Constructs were packaged and used individually for infection. Nontransduced cells were eliminated by treatment with 1 mg/mL puromycin for 72 hours. See also supplemental Methods and supplemental Tables 2 and 3 .
Pharmacologic inhibitors
See supplemental Methods.
Cell proliferation assay
Cells (5 3 10 3 ) were suspended in 100 mL RF10 6 inhibitor and cultured in triplicate in a 96-well plate. Where indicated, cells were treated with imatinib or KPT-330 at indicated concentrations. Following 72 hours, CellTiter 96 AQueous One Solution MTS Reagent (Promega) was added according to the manufacturer's instructions. Viable cells were quantified by measuring dye absorption in each well at 490 nm using an Epoch Microplate Spectrophotometer (BioTek Instruments, Winooski, VT).
Colony formation assay
Primary CML CD34 1 cells and cell lines were suspended in MethoCult H4230 (StemCell Technologies) under the indicated conditions and colonyforming unit granulocyte-macrophage colonies were counted under an inverted microscope after 10 to 15 days. See also supplemental Methods.
Apoptosis assays
Apoptosis was assayed by staining with allophycocyanin-conjugated annexin V in combination with 7-aminoactinomycin D (BD Biosciences, San Jose, CA). Cells were analyzed for fluorescence on a Guava easyCyte HT Flow Cytometer (Millipore).
Nucleocytoplasmic fractionation
Supernatant containing the cytoplasmic fraction was diluted in 10 mM N-2hydroxyethylpiperazine-N9-2-ethanesulfonic acid, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol, pH 7.9 0.2% nonyl phenoxypolyethoxylethanol-40, followed by centrifugation (7500 rpm, 2 minutes). Nuclei were lysed in standard radioimmunoprecipitation assay buffer. See also supplemental Methods.
Immunoblot analysis
Antibodies used were as follows: rabbit anti-lamin B1 (Abcam), mouse anti-phospho-c-ABL (recognizing Y412), and rabbit anti-RAN (Cell Signaling Technology, Danvers, MA); goat anti-I2PP2A (SET) and mouse anti-a-tubulin (Sigma, St. Louis, MO); mouse anti-c-ABL (Calbiochem, San Diego, CA); and mouse anti-p53 (Santa Cruz Biotechnology Inc., Santa Cruz, CA). Antibodies against c-ABL and phospho-c-ABL were used to measure total vs activated BCR-ABL1, respectively. See also supplemental Methods.
Nucleofection
For ectopic expression of RanGAP in K562 S and AR230 S cells, the pDsRed1-N1 RanGAP plasmid (Addgene, Cambridge, MA) 18 Results K562 R and AR230 R cells exhibit BCR-ABL1 kinase-independent TKI resistance K562 S and AR230 S cells and imatinib-resistant derivatives, K562 R and AR230 R , were cultured with and without 1 mM imatinib for 24 hours followed by immunoblot analysis of BCR-ABL1 ( Figure 1A ). BCR-ABL1 expression was increased in K562 R compared with K562 S cells, but equal in AR230 R vs AR230 S cells. 16 In both model systems, 1 mM imatinib reduced BCR-ABL1 phosphorylation ( Figure 1A ), implicating BCR-ABL1 kinase-independent mechanisms of TKI resistance. No kinase domain mutations were detected upon sequencing of the BCR-ABL1 kinase domain (data not shown). 16 The imatinib IC 50 in TKI-resistant vs TKI-sensitive K562 and AR230 cells was measured by treating with graded concentrations of imatinib for 72 hours and quantifying cell viability. As expected, the IC 50 for imatinib was ;10-fold higher in K562 R and AR230 R cells when compared with TKI-sensitive parental controls ( Figure 1B ). Together, these data indicate that K562 R and AR230 R cells are suitable in vitro models for studying BCR-ABL1 kinaseindependent TKI resistance. 16 shRNA library screening of parental K562 S cells yields consistent results in intra-and interlaboratory experiments Equal numbers (1.8 3 10 7 ) of K562 S and K562 R cells in steady state were transduced with the HM1 library, with experiments in K562 R cells performed in triplicate (Figure 2A ). Fluorescence-activated cell sorter analysis revealed #30% RFP-positive cells, consistent with a multiplicity of infection of 1. Half of the cells were collected 72 hours after transduction as a baseline control for barcode abundance.
The second half was puromycin-selected for 3 days, then cultured for an additional 9 days. Approximately 27 000 unique barcodes were recovered in each experiment, consistent with comprehensive representation of library complexity. We next ascertained reproducibility of the screen and determined that fold-changes in barcode abundance were highly correlated in both intralaboratory (3 independent experiments on K562 R cells) and interlaboratory (experiments conducted at the Huntsman Cancer Institute with K562 S cells were compared with Cellecta) comparisons ( Figure 2B ). These data show that the approach yields reproducible results, even if performed in different laboratories.
Identification and validation of resistance genes
To prioritize genes with a potential role in BCR-ABL1 kinaseindependent resistance, we selected candidates based on the following: (1) fold-change of barcode abundance in K562 R cells more than or equal to twofold compared with K562 S cells, and (2) this degree of fold-change was observed in at least 2 shRNAs targeting the same gene. Based on these considerations, the customized algorithm identified and ranked 50 genes putatively associated with BCR-ABL1 kinase-independent imatinib resistance in K562 R cells (supplemental Table 4 ). Major protein functions represented included nucleocytoplasmic transport, proteasomal protein degradation, chromatin remodeling, protein biosynthesis, cell cycle regulation, apoptosis, antioxidation, ubiquitination, and DNA repair (supplemental Table 4 ). As a negative control, a large number of luciferase shRNA sequences (21 compared with the maximum of 6 sequences for any other single gene) were assessed; none of these resulted in even a 35% fold-change. We next arbitrarily selected 5 of the 30 highest-ranking genes and 1 gene with a lower rank (RAD54L, rank: 92) for further validation, in each case using the shRNA with the highest percent reduction during the library screen. K562 S and K562 R cells were transduced with tetracycline-inducible constructs for expression of individual candidate shRNAs (see supplemental Table 2 ). Cells were infected with lentivirus, RFP-selected, and cultured 60.1 mg/mL doxycycline for 72 hours followed by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) to assess knockdown. Expression was reduced by at least 60% in all cases (range: 60% to 95%), confirming shRNA functionality ( Figure 3A ). To investigate shRNA effects on cell growth, cells were analyzed by MTS assay 72 hours after addition of doxycycline. In 5 of the 6 genes (83%) selected for validation, shRNA knockdown significantly reduced viable cell numbers in K562 R cells ( Figure 3B ). Downregulation of these 5 genes (BCL2L1, CIP29, GATA1, RAD54L, and RPS6) led to a greater reduction of viability in K562 R compared with K562 S cells; only the shRNA targeting RPS6 had significant effects on K562 S cells ( Figure 3B ). These data confirm that the library screen predominantly identified genes with a critical role in TKI resistance.
RAN is a critical mediator of BCR-ABL1 kinase-independent resistance
Two genes involved in nucleocytoplasmic protein transport, RAN (rank: 4) and XPO1 (rank: 5), were among the top candidate resistance genes identified by the shRNA library screen (supplemental Table 4 ). Because RAN is known to regulate XPO1, we further investigated its role as a regulator of nucleocytoplasmic transport in BCR-ABL1 kinase-independent TKI resistance. Of note, XPO1 was recently shown to play a role in TKI resistance and blastic transformation. 19 Importantly, RAN knockdown in the shRNA library screen resulted in fourfold reduction of barcode abundance in K562 R compared with K562 S cells (supplemental Table 4 ). We first analyzed RAN protein expression in 4 cell lines, K562 S , K562 R , AR230 S , and AR230 R , by immunoblot analysis. RAN protein levels in steady-state TKI-resistant cells (1 mM imatinib) were equal to that of TKI-sensitive cells (no imatinib) ( Figure 4A , whole cell lysate). However, when we assessed the nucleocytoplasmic localization of RAN, higher levels were seen in the cytoplasm of TKI-resistant compared with TKI-sensitive cells ( Figure 4A , fractionation), suggesting a potential role of RAN in TKI resistance. We next measured the effects of shRNA-mediated RAN downregulation in K562 S vs K562 R and AR230 S vs AR230 R cells. shRAN reduced RAN mRNA expression by 40% to 60% in all cell lines tested ( Figure 4B ). RAN knockdown following exposure to doxycycline (72 hours, 0.1 mg/mL) induced apoptosis in TKI-sensitive and For personal use only. on March 13, 2015. by guest www.bloodjournal.org From TKI-resistant K562 and AR230 cells in vitro ( Figure 4C ). To isolate the effects of RAN knockdown on imatinib sensitivity, we determined the ratio of viable cells in doxycycline-treated vs untreated cells cultured in graded concentrations of imatinib. In consideration of the sensitivity of K562 S and AR230 S cells to imatinib, the experiment was performed in low imatinib concentrations (0.1-0.8 mM), with viable cells quantified by MTS assay 72 hours following addition of doxycycline. Consistent with apoptosis data, RAN knockdown suppressed cell proliferation at low imatinib concentrations in K562 S and K562 R cells ( Figure 4D , left). However, at higher concentrations of imatinib ($0.4 mM), shRAN continued to reduce viable cell numbers in K562 R cells, with no additional effects in K562 S cells, which are already being killed by imatinib alone. A similar, less pronounced effect was observed in AR230 R vs AR230 S cells ( Figure 4D , right). These data are consistent with the observation that the TKI-resistant lines maintain levels of RAN in the presence of imatinib that are comparable with that of TKIsensitive lines in the absence of imatinib ( Figure 4A-B ). At the highest concentration of imatinib (0.8 mM), RAN knockdown reduced growth of K562 R and AR230 R cells but had no additional effects on K562 S and AR230 S cells, consistent with a critical role of RAN in the resistant cells. We therefore investigated the effects of RAN knockdown on the resistant cell lines at higher imatinib concentrations. RAN shRNA-transduced K562 R and AR230 R cells were treated with imatinib (1-64 mM) 6 doxycycline, and proliferation was measured at 72 hours by MTS assay. RAN knockdown reduced the IC 50 of imatinib by more than twofold in K562 R and AR230 R cells compared with controls not treated with doxycycline ( Figure 4E ). Taken together, these data suggest that imatinib resistance in K562 R and AR230 R cells is, at least in part, dependent on RAN, and RAN knockdown does not add to the effect of sufficiently high imatinib concentrations on TKI-sensitive K562 S and AR230 S cells.
Ectopic expression of RAN-GTPase activating protein (RanGAP) enhances imatinib resistance
Nucleocytoplasmic transport is dependent on a RAN-guanosine triphosphate (GTP)/guanosine diphosphate gradient between the nucleus and cytoplasm, facilitated by the RAN guanine nucleotide exchange factor, RCC1. 20-22 GTP-bound RAN associates with the nucleocytoplasmic shuttling protein, XPO1, which then binds cargo proteins such as p53. 19, 21, 23, 24 Once the complex has been transported to the cytoplasm, RAN-GTP is converted to RANguanosine diphosphate by RanGAP, promoting release of cargo into the cytoplasm. To test the hypothesis that ectopic expression of RanGAP would enhance RAN nucleocytoplasmic shuttling, thereby inducing imatinib resistance in K562 S cells, we transduced K562 S cells with a RanGAP expression vector (pDsRed1-N1-RanGAP) or empty vector and tested for sensitivity to graded concentrations of imatinib by viable cell counting 120 hours following transduction. RanGAP overexpression was confirmed by qRT-PCR ( Figure 5A ). Ectopic expression of RanGAP increased the viability and number of K562 S cells compared with empty vector controls up to a maximum of threefold at 2 mM imatinib ( Figure 5B ). These experiments were confirmed in the TKIsensitive AR230 S cell line, in which ectopic RanGAP expression abolished the effects of 2.0 mM imatinib (supplemental Figure 2) . These data support a direct role for RAN in promoting BCR-ABL1 kinase-independent TKI resistance. 19 
Inhibition of the RAN-XPO1-SET pathway impairs survival of CML cells with BCR-ABL1 kinase-independent TKI resistance
Because RAN-dependent nucleocytoplasmic transport is involved in BCR-ABL1 kinase-independent TKI resistance, and XPO1 regulates SET subcellular localization, 19 we hypothesized that RAN may be part of the XPO1-SET pathway in BCR-ABL1 kinaseindependent TKI resistance. 19, 25 We initially analyzed SET protein levels in TKI-resistant vs TKI-sensitive K562 and AR230 cells by immunoblot. Similar to RAN, SET protein levels in steady-state TKI-resistant cells (in the presence of imatinib) were equal to that of TKI-sensitive parental controls (no imatinib) ( Figure 6A , whole cell lysate). However, when we assessed nucleocytoplasmic localization of SET, higher levels were seen in cytoplasm of TKI-resistant compared with TKI-sensitive cells ( Figure 6A , fractionation), consistent with its reported role in TKI resistance. 19 We next analyzed the effects of RAN knockdown on expression and subcellular localization of SET in TKI-sensitive vs TKI-resistant CML cells. Consistent with RAN knockdown at the mRNA level, doxycycline (72 hours, 0.1 mg/mL) reduced RAN protein levels by 40% to 60% in all cell lines tested ( Figure 6B ). Importantly, shRAN reduced levels of cytoplasmic SET in TKI-resistant K562 R and AR230 R cells ( Figure 6B ); some reduction was also observed in K562 S cells. These data suggest that RAN is required for increased cytoplasmic SET expression, supporting a role for RAN in SET-mediated TKI resistance.
KPT-330 (Selinexor) is an inhibitor of XPO1 that irreversibly binds to cysteine-528, the critical XPO1 cargo-binding residue. 19, 26 Similar to shRNA-mediated RAN knockdown ( Figure 4C BLOOD, 12 MARCH 2015 x VOLUME 125, NUMBER 11 NUCLEOCYTOPLASMIC TRANSPORT IN TKI RESISTANCE 1777 Figure 3 ). However, when CML cell lines were treated with graded concentrations of KPT-330 for 72 hours, the IC 50 was 2-and 1.4-fold lower in K562 R and AR230 R cells, respectively, compared with parental counterparts (supplemental Table 5 ), suggesting that TKIresistant cells are indeed more sensitive to XPO1 inhibition than TKI-sensitive cells. Therefore, KPT-330 was used to inhibit XPO1 in subsequent experiments. Importantly, the highest concentration of KPT-330 with no effect on colony formation ( Figure 7Aii ) or apoptosis (supplemental Figure 4A ) of cord blood CD34 1 cells, 50 nM, was chosen for experiments with CD34 1 cells from newly diagnosed and TKI-resistant CML patients. In addition, shRAN had no effect on colony formation by normal cord blood CD34 1 cells ( Figure 7Ai ). We next tested the effects of shRAN on CD34 1 cells from newly diagnosed CML patients (n 5 4). RAN knockdown was confirmed by quantitative real-time PCR analyses (supplemental Figure 4B ). Although RAN knockdown alone had no effect on survival ( Figure 7Bi ) or apoptosis (supplemental Figure 4C ) of CD34 1 cells from newly diagnosed CML patients, it significantly enhanced the effects of imatinib, reducing colony formation and increasing apoptosis by 46% (P , .005) and 44% (P , .001), respectively, compared with controls treated with imatinib alone. A similar set of experiments was performed using KPT-330 to pharmacologically inhibit RAN/XPO1-mediated nucleocytoplasmic transport. KPT-330 reduced colony formation by 37% (P 5 .06) in the absence of imatinib, with no observed changes in apoptosis (supplemental Figure 4D ). In contrast, combination of KPT-330 with imatinib enhanced this effect to 55% compared with KPT-330 alone (P , .02; Figure 7Bii ), with an associated 51% increase of apoptosis compared with cells treated with imatinib alone. Next we assessed the effect of KPT-330 on the subcellular localization of RAN and SET in CD34 1 cells from newly diagnosed CML-CP patients harboring native BCR-ABL1. Although imatinib treatment had no effect on nucleocytoplasmic distribution of RAN or SET (Figure 7Biii ), inhibition of XPO1 with KPT-330 resulted in increased nuclear localization of each protein, in addition to nuclear accumulation of p53 (a known target of this pathway); thus, p53 induction may be in part responsible for the observed effects of KPT-330 on survival of CML CD34 1 cells. CML CD34 1 cells treated with both imatinib and KPT-330 exhibited a high level of cell death, precluding assessment of protein localization by immunoblot analysis.
We next assessed the effects of RAN and XPO1 inhibition on CD34 1 cells from CML patients with TKI resistance (n 5 4). Sanger sequencing revealed exclusively native BCR-ABL1 in 3 patient samples, indicating kinase-independent resistance. A fourth patient harbored the T315I gatekeeper kinase domain mutation (see supplemental Table 1 ) and thus exhibits kinase-dependent TKI resistance with respect to imatinib, nilotinib, and dasatinib. In samples from 2 patients with kinase-independent resistance, shRAN significantly reduced colony formation in the presence of 2.5 mM imatinib (P , .01). A reduction of colonies was also observed in the absence of imatinib, but did not reach statistical significance (P . .1) ( Figure 7Ci) . Similarly, addition of 50 nM KPT-330 to colony-forming assays significantly reduced survival in the presence (P , .001) but not absence (P . .1) of imatinib in all 3 samples tested ( Figure 7Ci ). Neither shRAN nor KPT-330 had any effect alone or in combination with imatinib on colony formation by CD34 1 cells from the patient with BCR-ABL1 T315I (Figure 7Cii ). These data link RAN to the XPO1-SET pathway and indicate that inhibition of either RAN or XPO1 reduces survival of primary CML cells from newly diagnosed and TKI-resistant patients. In both settings, the effects are partially dependent on simultaneous inhibition of BCR-ABL1 kinase activity.
Discussion
Many patients with CML-CP who start imatinib attain stable complete cytogenetic and major molecular responses. 2 However, it is estimated that ;20% to 40% of newly diagnosed CML-CP patients eventually require alternative therapies because of intolerance or resistance. 3, 4, [27] [28] [29] [30] Missense mutations in the BCR-ABL1 kinase domain [5] [6] [7] explain only 30% to 40% of clinical imatinib-resistance cases. 8 BCR-ABL1 kinase-independent mechanisms 16 that are currently not well understood activate alternative pathways that underlie resistance in patients without explanatory BCR-ABL1 mutations. This phenomenon is not limited to CML, as FLT3-independent mechanisms have been implicated in acute myeloid leukemia resistance to FLT3-targeting drugs. 31, 32 To identify signaling pathways associated with BCR-ABL1 kinase-independent TKI resistance, we performed a lentiviral shRNA library screen on K562 cells (K562 S , imatinib-sensitive) and an imatinib-resistant derivative line (K562 R ) that maintains viability despite suppression of BCR-ABL1 kinase activity (Figure 1 ). Genes with a potential role in resistance were selected based on criteria designed to minimize false-positive results. RAN and XPO1 (CRM1), 2 interacting proteins with key functions in nucleocytoplasmic transport, were among the top 5 candidates, suggesting a role for this pathway in TKI resistance. RAN and XPO1 synergize to promote nucleocytoplasmic shuttling of cargo proteins through the nuclear pore complex. 33 Although binding of XPO1 to either Figure 7 . Inhibition of RAN/XPO1 impairs survival of CML but not normal CD34 1 cord blood cells. (A) CD34 1 cells from normal cord blood (n 5 2) were either infected with doxycycline-inducible shRAN and plated in semisolid medium with and without 2.5 mM imatinib (i) or plated in semisolid medium in the presence or absence of graded concentrations of KPT-330 (ii-iii). Colonies were counted after 14 days. RAN inhibition had no effect on survival of normal CD34 1 cord blood cells. (B) CD34 1 cells from newly diagnosed CML patients were either infected with shRAN (i) or treated with KPT-330 (ii) and analyzed for colony formation in the indicated conditions. Inhibition of XPO1 by treatment with KPT-330 also resulted in enhanced levels of nuclear RAN, SET, and p53 in CD34 1 cells from newly diagnosed CML patients. Lamin B was analyzed to control for nuclear fractionation and a-tubulin for cytoplasmic fractionation. (C) CD34 1 cells from patients with clinical TKI resistance were either infected with shRAN or treated with KPT-330 and analyzed for colony-forming ability. shRAN and KPT-330 significantly reduced survival of CML CD34 1 cells from TKI-resistant patients with wild-type BCR-ABL1 (i), but not from a patient with BCR-ABL1 T315I (ii). Error bars represent SEM; *P , .05. Because only 1 BCR-ABL1 T315I patient sample was analyzed, standard errors are not provided.
RAN or cargo protein alone is weak, simultaneous binding of RAN and cargo to XPO1 increases its affinity to both by 1000-fold. 24, 34 XPO1/RAN-mediated export is increased in a variety of cancers. Mechanistically, overexpression of XPO1 enhances export of nuclear tumor suppressor proteins such as p53, BRCA1, allophycocyanin, and NMP1, resulting in drug resistance. 33 Overexpression of XPO1 has also been associated with drug resistance and poor outcome in many solid tumors such as glioblastoma, cervical and ovarian cancer, [35] [36] [37] and various hematologic malignancies, including myeloma, 38 chronic lymphocytic leukemia, 26 T-cell acute lymphoblastic leukemia, acute myeloid leukemia, [39] [40] [41] and BCR-ABL1-driven blastic transformation. 19, 42 In the shRNA library screen, shRAN-infected cells were depleted by fourfold in K562 R compared with K562 S cells (supplemental Table 4 ) following 9 days in culture. As K562 R cells are grown in 1 mM imatinib, we performed a series of experiments to assess the effect of RAN knockdown on sensitivity to imatinib. We found that RAN knockdown alone induced apoptosis to comparable levels in TKI-sensitive and TKI-resistant cells ( Figure 4C ). However, RAN knockdown enhanced the effects of imatinib on TKI-resistant cells to a greater degree than on TKI-sensitive cells ( Figure 4D -E), indicating that upon imatinib challenge, resistant cells become more dependent on RAN than sensitive cells. Importantly, targeting the RAN/XPO1 shuttling pathway enhanced the effects of imatinib on primary CML-CP cells, with no effect on normal CD34 1 cord blood cells (Figure 7) . The fact that both our TKI-resistant cell lines 16 and primary CML patient samples (supplemental Table 1 ) demonstrate cross-resistance to the second-generation TKIs, dasatinib and nilotinib, suggests the RAN/XPO1 shuttling pathway may also be responsible for resistance to TKIs other than imatinib.
Our data establish a link between RAN and the XPO1-SET pathway in CML and TKI resistance. Cytoplasmic SET promotes leukemogenesis in CML and other leukemias by inhibiting PP2A, a tumor suppressor phosphatase that dephosphorylates critical proteins such as signal transducer and activator of transcription 5. 25 Thus, it is conceivable that reduced PP2A activity plays a role in BCR-ABL1 kinase-independent TKI resistance of CML-CP cells with native BCR-ABL1. Moreover, Balabanov et al demonstrated that altered phosphorylation of several RAN pathway-associated proteins may play a role in survival of BCR-ABL1-positive leukemic stem cells, 43 implicating RAN in the TKI resistance of CML stem cells.
Interestingly, the shRNA library screen identified many other pathways whose roles in TKI resistance are yet to be experimentally validated. Among these pathways are genes involved in proteasomal protein degradation, chromatin remodeling, protein biosynthesis, cell cycle regulation, apoptosis, antioxidation, ubiquitination, and DNA repair. In particular, 5 of the top 50 genes (PSMA1, UBE1, NEDD8, PSMD3, and PSMD1) are associated with proteasomedependent protein degradation, which has been implicated in TKI resistance of CML stem and progenitor cells. 44 In addition, 3 of the top 50 genes (TXN, RPA3, and MUS81) are associated with DNA damage or repair pathways, adding to the observation of increased homologous recombination repair in samples from imatinib nonresponders, 45 and a report implicating RAD52 as a target to enhance the effects of TKIs on CML cells. 46 Drug resistance remains a significant clinical problem in targeted cancer therapy. In the case of CML, our function-first shRNA library approach led to the identification of RAN and XPO1 as critical mediators of BCR-ABL1 kinase-independent TKI resistance. The shRNA library approach described here may be useful for clinical situations in which drug resistance develops in the absence of mutations in the primary drug target and may prove useful for personalized diagnostics and drug therapy. Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society a number of oncogenic proteins and receptors (eg, p53, c-Myc, Akt, cyclin D, Cdk4, ALK) that are deregulated in lymphoma, preventing their degradation (see figure) . Overexpression of HSPs has been documented in different lymphoma subtypes and it contributes to the oncogenic process. 3 Inhibition of HSPs that specifically bind to proteins involved in lymphomagenesis may be of great value for the treatment of these diseases.
The authors show that HSPH1, a subgroup of the HSP70 family of proteins, is expressed in B-cell lymphomas, preferentially in those with a high proliferation rate. HSPH1 protein expression directly correlates with BCL-6 and c-Myc protein expression in aggressive lymphoma cell lines. In fact, the authors convincingly show that HSPH1 directly binds to BCL-6 and c-Myc, thus acting as a chaperone for these proteins. Most important, in a series of in vitro studies, the authors show that HSPH1 inhibition directly downregulates BCL-6 and c-Myc, which leads to a significant decrease in cell proliferation. To further evaluate this concept, the group tested the growth of an aggressive B-cell lymphoma line in an in vivo model. Mice transplanted with HSPH1-knocked-down tumors had significantly longer survival, and the protein levels of BCL-6 and c-Myc in the tumor cells were decreased, in agreement with the reported in vitro studies. In addition, tumor angiogenesis was also reduced, consistent with the inhibition of the provascularization properties of c-Myc, which may additionally contribute to the antitumoral effect.
Finally, to enhance the clinical relevance of this finding, the investigators analyzed the expression of HSPH1 in primary B-cell lymphomas. In a previous study, they showed that HSPH1 protein expression was correlated with the tumor proliferation rate. Thus, low-grade lymphomas showed a significantly lower HSPH1 tumor expression than high-grade lymphomas. 4 In particular, diffuse large B-cell lymphoma (DLBCL) with a high Ki-67 index and Burkitt lymphoma appear to have higher HSPH1 expression. In line with these data, HSPH1 protein expression in a transformed DLBCL was significantly increased compared with the expression seen in the indolent lymphoma. Remarkably, in c-Myc 1 lymphomas, HSPH1 protein expression correlated with that of c-Myc.
Overall, these data suggest that HSPH1 inhibition could potentially be useful in those lymphomas with c-Myc alterations (ie, Burkitt and the so-called "double-hit" lymphomas-mature B-cell lymphomas with a translocation affecting c-Myc in combination with another translocation usually affecting bcl-2). This is of paramount relevance, in particular for the latter, amounting to a poor-prognosis lymphoma for which no effective therapies have been developed so far. 5 A few studies have addressed the inhibition of other HSPs as a treatment of B-cell lymphoma. In particular, HSP90, an important chaperone involved in cancer, 6 is frequently expressed in DLBCL and, importantly, its expression highly correlates with BCL-6, 7 a transcription factor that is frequently deregulated in DLBCL. Experimental in vitro and in vivo studies showed that a purine-derived HSP90 inhibitor, PUH71, selectively killed primary DLBCLcoexpressing BCL-6 and HSP90, and this approach is being translated into the clinical scenario in patients with lymphoma with the new available HSP90 inhibitors. Although early trials with HSP inhibitors in lymphoma patients have not shown impressive clinical activity, it may be envisioned that a combination of different HSP inhibitors targeting distinct oncogenic proteins may improve their efficacy and may add value to conventional immunochemotherapy.
Pharmacologic inhibitors of HSPH1 have yet to be developed, but the discovery of HSPH1 as a chaperone of c-Myc in B-cell lymphoma presents an important opportunity to design rational, molecularly based treatments for c-Myc-dependent B-cell lymphomas such as Burkitt lymphoma and the "double-hit" DLBCL.
Conflict-of-interest disclosure: The author declares no competing financial interests. n A "RANning" leap with "XPOrt" into TKI resistance I t is increasingly the case that a deeper knowledge of the crosstalk between leukemic stem and progenitor cells and their bone marrow microenvironment is needed to fully understand how the latter influences leukemia development, progression, and resistance to targeted therapies. This also appears to be true for those cases of CML that show BCR-ABL1 kinase-independent resistance to TKI therapy.
Given that missense mutations in the BCR-ABL1 kinase domain explain only 30% to 40% of clinical imatinib resistance cases, and that ;20% to 40% of newly diagnosed CML patients eventually require alternative therapies due to TKI intolerance or resistance, 2 the understanding of the still largely unclear molecular events regulating drug resistance in patients without BCR-ABL1 mutations appears to be of extreme clinical relevance. As also indicated by Khorashad et al, 1 this is true not only for CML but also for those cases of acute myeloid leukemia (AML) showing FLT3-independent resistance to FLT3-targeting drugs. 3 Mechanistically, Khorashad et al 1 have identified signaling pathways associated with BCR-ABL1 kinase-independent TKI resistance by performing a lentiviral shRNA library screen on K562 cells (K562S, imatinib sensitive) and an imatinib-resistant derivative line (K562R) that maintains viability despite suppression of BCR-ABL1 kinase activity.
Genes with a potential role in resistance were selected based on criteria designed to minimize false-positive results. The RAS-related nuclear protein RAN and the karyopherin b family member XPO1 (exportin-1, also called chromosome maintenance protein 1 [CRM1]), two interacting proteins with key functions in nucleocytoplasmic transport, were among the top 5 candidates, suggesting a role for these factors and corresponding signal transduction pathways in BCR-ABL1-independent TKI resistance (see figure) .
RAN is involved in the transport of proteins across the nuclear envelope by interacting with karyopherins and changing their ability to bind or release cargo molecules. Cargo proteins containing nuclear localization signals are bound by importins and transported into the nucleus. Inside the nucleus, RAN-guanosine triphosphate (GTP) binds to importin and releases the import cargo. Cargo that needs to exit the nucleus into the cytoplasm binds to exportin in a ternary complex with RAN-GTP.
Upon hydrolysis of RAN-GTP to RAN-guanosine diphosphate (GDP) outside the nucleus, the complex dissociates and the export cargo is released. Khorashad et al 1 found that RAN and XPO1 synergize to promote nucleocytoplasmic trafficking of cargo proteins through the nuclear pore complex. Although binding of XPO1 to either RAN or cargo protein alone is weak, simultaneous binding of RAN and cargo to XPO1 increases its affinity to both by 1000-fold (see figure) . Notably, XPO1-mediated nucleocytoplasmic protein trafficking regulates the function of tumor suppressors and oncogenes (eg, SET, PP2A, p53, p21, p27, NF-kB, Mcl-1, myc, Rb, BRCA1, APC, NMP1, and FoxO3a) that play an important role in survival and proliferation of normal and cancer cells, including different types of lymphoid and myeloid and acute and chronic leukemias (reviewed in Turner et al 4 
and Tan et al 5 ).
Interestingly, Khorashad et al 1 also identified through the shRNA library screen many other pathways whose roles in TKI resistance are yet to be experimentally validated. Among these pathways are genes involved in proteasomal protein degradation, chromatin remodeling, protein biosynthesis, cell-cycle regulation, apoptosis, antioxidation, ubiquitination, and DNA repair. In particular, 5 of the top 50 genes (PSMA1, UBE1, NEDD8, PSMD3, and PSMD1) are associated with proteasome-dependent protein degradation, which has been implicated in TKI resistance of leukemic stem and progenitor cells. 6 Thus, nuclear export and signaling linking the stem/progenitor cell to the microenvironment will further elucidate BCR-ABL-independent signaling in CML and AML. XPO1/RAN-mediated export was implicated in many types of solid tumors and hematologic malignancies. [7] [8] [9] [10] Given that XPO1 is a critical regulator of cell proliferation and survival, which is not only overexpressed but also described as a poor prognostic factor in different hematologic malignancies, it is not surprising that different inhibitors of XPO1-mediated export through the nuclear pore complex have been developed. Among these, the selective inhibitors of nuclear export (SINE; Karyopharm Therapeutics) are leptomycin B-based small molecules that irreversibly bind to Cys528 in the cargo-binding groove of XPO1 to prevent Mechanisms of oncogene kinase-independent resistance to TKI therapy in CML with wild-type BCR-ABL1 and FLT3-ITD 1 AML. The expression of the nuclear export factors RAN and XPO1 was found to be increased in CML and AML in an oncogene kinase-independent manner and likely through either signals generated by the microenvironment or by cell-autonomous BCR-ABL or FLT3-ITD kinase-independent signals (A). This results in increased nuclear export of their cargo that also is comprehensive of oncogenic signal transducers (eg, SET) and tumor-suppressor proteins (eg, p53) that if delocalized become activated and inactivated, respectively. Such an effect together with the BCR-ABL1-or FLT3-ITD-generated oncogenic signals will both enhance proliferation and/or survival of myeloid progenitors. Interestingly, Khorashad et al 1 show that the activity of XOP1 and RAN seems to specifically control those oncogene kinase-independent molecular events leading to resistance to TKI-induces apoptosis. Khorashad et al 1 reported that inhibition of nuclear export by downregulation of RAN or pharmacologic inhibition of XPO1 activity by the clinically relevant karyopherin inhibitor KPT-330 results in nuclear accumulation of their cargo and, consequently, restored sensitivity of leukemic progenitors to TKI-induced inhibition of proliferation and/or survival and restoration of sensitivity to TKI treatment (B). figure) . Previous studies have shown that the closely related SINE compounds KPT-251, KPT-276, and KPT-330 have strong antileukemic activity and minimal and acceptable adverse effects in acute myelogenous leukemia and CML in blastic transformation. [8] [9] [10] Notably, the clinically relevant XPO1 inhibitor KPT-330 leads to apoptosis and impairment of leukemic clonogenic potential of leukemic but not normal CD34 1 progenitors and significantly increased survival of leukemic mice. Mechanistically, KPT-330 altered the subcellular localization of leukemiaregulated factors, including RNA-binding heterogeneous nuclear ribonucleoprotein A1 and the oncogene SET, thereby inducing reactivation of protein phosphatase 2A tumor suppressor and inhibition of BCR-ABL1 in CML blast crisis cells. Because XPO1 is important for leukemic cell survival, KPT-330 may represent an alternative therapy for TKI-refractory Ph 1 leukemias. 8 Thus, the notion that RAN/XPO1 activity controls oncogene kinase-independent drug resistance in both AML and CML 1 further supports the use of the available XPO1 inhibitors in therapeutic protocols for those patients. Notably, the SINE KPT-330 is currently in clinical trials for advanced hematologic malignancies and solid tumors (NCT01607892 and NCT01607905). Furthermore, the work of Khorashad et al 1 opens the gateway to characterize microenvironment-generated signals responsible for altered XPO1 expression/activity and, consequently, to develop strategies to efficiently counteract drug resistance in AML as well as in those cases of CML not responding to TKI monotherapy.
XPO1-cargo interactions (see
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In this issue of Blood, Bartels and colleagues demonstrate that acetylation of the transcription factor CCAAT enhancer binding protein e (C/EBPe) is essential for terminal neutrophil granulocyte differentiation. 1 N eutrophils, the most abundant granulocytes, are essential for host innate immune defense. Neutropenia results from damage to the bone marrow or depletion or destruction of neutrophils by drugs, diseases, or congenital disorders that block neutrophil differentiation. Neutropenic individuals are extremely susceptible to bacterial infection, and febrile neutropenia increases the risk of mortality in cancer patients receiving myelosuppressive chemotherapy. 2 Prophylactic use of granulocyte colonystimulating factor (G-CSF) reduces mortality by increasing neutrophil numbers. 2 A better understanding of the mechanisms that regulate granulopoiesis and terminal neutrophil differentiation could spur development of new strategies to overcome neutropenia and improve clinical outcomes.
The C/EBP transcription factor family is essential for granulopoiesis and terminal differentiation of neutrophils. 3 C/EBPa is predominantly expressed in immature myeloid cells, and lack of expression leads to a block at the myeloblast stage. 3 C/EBPb is expressed from the metamyelocyte stage and on during maturation. 3 C/EBPb-deficient mice display normal granulocyte differentiation and steadystate levels of neutrophils but are unable to produce neutrophils in response to cytokine Acetylation of C/EBPe is essential for terminal neutrophil differentiation and function. C/EBPe is acetylated during granulocytic differentiation toward neutrophils by lysine acetylases (KAC, eg, p300) or lysine deacetylase inhibitors (KDACi, eg, nicotinamide inhibiting KDAC SIRT1). Acetylation on K121 and K198 is essential for terminal differentiation of neutrophils and expression of secondary granule proteins. Differential acetylation of C/EBPe could be important for determining differentiation along the neutrophil or eosinophil lineages. Table S1 . Primary specimens used for these studies. 
Supplemental Tables
Supplemental Materials and Methods
Imatinib-sensitive and -resistant cell lines.
For complete removal of imatinib from K562 R and AR230 R cells prior to use in assays, resistant derivatives were washed out following a stringent protocol 71 . Resulting lines were confirmed to harbor native BCR-ABL1 using conventional Sanger sequencing in both directions with BigDye terminator chemistry on an ABI3730 instrument 72 .
Patient samples. Mononuclear cells (MNCs) were separated by density centrifugation on Ficoll-
Hypaque (Nycomed, Zürich, Switzerland) from normal cord blood or peripheral blood or bone marrow of newly diagnosed CML patients or CML patients with clinical resistance to two or more TKIs. CD34 + cells were isolated from MNCs using an autoMACS system (Miltenyi Biotec, San Diego, CA), assessed for purity with a Guava easyCyte HT Flow Cytometer (Millipore, Billerica, MA) and cryopreserved. BCR-ABL1 genotype was determined by conventional sequencing as described above. shRNA library screen. To calculate the multiplicity of infection (MOI), graded volumes of concentrated lentivirus were added to K562 S cells and the plates were centrifuged at 1800 rpm for 90 minutes at 32°C. After 18 h, the cells were resuspended in fresh medium, cultured for 72 h and analyzed for RFP expression on a FACSCanto Flow Cytometer. The volume of virus required for an MOI of 1 was calculated as recommended by Cellecta (Pooled Barcoded Lentiviral shRNA library v5, http://www.cellecta.com/resources/protocols).
Tetracycline-inducible constructs and mRNA expression analysis.
For shRNA and target sequences see Supplemental Table S2 . Knockdown of target genes was validated by qRT-PCR 72 h following addition of doxycycline. RNA was extracted using the RNeasy Mini Kit (Qiagen) and
converted to cDNA using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). Gene expression was measured by real-time PCR using SsoAdvanced™ SYBR ® Green Supermix (Bio-Rad) in a CFX96 Real-Time PCR Detection System (Bio-Rad). For primer sequences see Supplemental Table S3 .
Pharmacologic inhibitors.
Imatinib was a kind gift of Novartis. Karyopharm Therapeutics provided KPT-330. IC50 values were assessed using a methanethiosulfate (MTS)-based viability assay (CellTiter 96 AQueous One; Promega) following treatment with graded concentrations of inhibitor for 72 h (see below).
Colony formation assay. Primary CML CD34 + cells were transduced with lentivirus, sorted for RFP (>95% purity) and cultured as described above. 2.2x10 3 cells were suspended in MethoCult™ H4230 (StemCell Technologies) supplemented with CC100 with or without 0.1 µg/mL doxycycline or 1 µM imatinib in duplicate. Where indicated, untransduced primary CML CD34 + cells were left untreated or treated with imatinib and/or KPT-330 at the indicated concentrations.
Colony forming unit granulocyte-macrophage colonies (CFU-GM) were counted under an inverted microscope after 10-15 days.
